PerkinElmer
check quantity

IntegriSense 750 Fluorescent Imaging Agent

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV10873
717.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

IntegriSense™ 750 is a targeted fluorescent imaging agent comprising a potent, selective non-peptide small molecule integrin avb3 antagonist and a near- infrared (NIR) fluorochrome. IntegriSense 750 has a shorter half life in tissue than IntegriSense 680. IntegriSense 750 washes out of tissues in ~ 96 hours to permit more frequent reinjection of the agent in longitudinal studies. This agent has been developed to enable in vivo visualization and quantification of integrin avb3 in tumor cells as well as in neovasculature, to monitor tumor growth, tumor angiogenesis, and treatment efficacy. Absorbance and fluorescence emission spectra of IntegriSense 750 in 1x PBS.

Specifications

Fluorescent Agent Type Targeted
Optical Imaging Classification Fluorescence Imaging
Product Brand Name IntegriSense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Angiogenesis, Atherosclerosis, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 750 nm
Resources, Events & More
  • All

Application Note

In Vivo Imaging of Atherosclerosis Disease Using FMT

Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).

PDF 1 MB
Multiplex 2D Imaging of NIR Molecular Imaging Agents on the IVIS SpectrumCT and FMT 4000

Epifluorescence (2D) imaging of superficially implanted mouse tumor xenograft models offers a fast and simple method for assessing tumor progression or response to therapy. This approach for tumor assessment requires the use of near infrared (NIR) imaging agents specific for different aspects of tumor biology, and this Application Note highlights the ease and utility of multiplex NIR fluorescence imaging to characterize the complex biology within tumors growing in a living mouse.

PDF 4 MB

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

Flyer

Technical Note

IntegriSense 750 (Protocol)

IntegriSense 750 in vivo fluorescent agent protocol

PDF 258 KB
IntegriSense™ 750 (Data Sheet)

IntegriSense™ 750 is a targeted fluorescence imaging agent comprising a potent, selective non-peptide small molecule integrin avß3 antagonist and a near-infrared (NIR) fluorochrome. This agent has been developed to enable in vivo visualization and quantification of integrin avß3 expressed in tumor cells as well as in neovasculature, to monitor tumor growth, tumor angiogenesis, and treatment efficacy.

PDF 57 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB